WIL2-NS (ATCC® CRL-8155)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Age 5 years
Gender male
Ethnicity Caucasian
Applications
transfection host
Derivation
The line was derived from the WIL-2 B cell line.
Clinical Data
male
Caucasian
5 years
Comments
This line does not secrete immunoglobulin.
The line was derived from the WIL-2 B cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11
D16S539: 11,12
D5S818: 12,13
D7S820: 9,12
F13A01: 6,7
F13B: 10
FESFPS: 11,12
LPL: 9,10
THO1: 8,9.3
TPOX: 8,11
vWA: 17,20
Name of Depositor TA Coons
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231

Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogren's syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494

Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987

Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992

Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992

Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231

Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogren's syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494

Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987

Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992

Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992

Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138